Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 91
Filter
1.
Sci Rep ; 12(1): 2006, 2022 02 07.
Article in English | MEDLINE | ID: mdl-35132164

ABSTRACT

Characterization of the microbial community is essential for understanding the symbiotic relationships between microbes and host insects. Chrysomya megacephala is a vital resource, a forensic insect, a pollinator, and a vector for enteric bacteria, protozoa, helminths, and viruses. However, research on its microbial community is incomprehensive, particularly at the pupal stage, which comprises approximately half of the entire larval development stage and is important entomological evidence in forensic medicine. For the first time, this study investigated the bacterial communities of C. megacephala pupae at different ages using third-generation sequencing technology. The results showed that C. megacephala has a diverse and dynamic bacterial community. Cluster analysis at ≥ 97% similarity produced 154 operational taxonomic units (OTUs) that belonged to 10 different phyla and were distributed into 15 classes, 28 orders, 50 families, 88 genera, and 130 species. Overall, the number of bacterial OTUs increased with the development of pupae, and the relative abundance of Wolbachia in the Day5 group was significantly lower than that in the other groups. Within the pupal stage, Proteobacteria, Firmicutes, and Bacteroidetes were the dominant phyla of bacteria. At the genus level, Wolbachia and Ignatzschineria coexisted, a rarely known feature. In addition, we found Erysipelothrix rhusiopathiae, the etiological agent of swine erysipelas, which is rarely identified in insects. This study enriches the understanding of the microbial community of C. megacephala and provides a reference for better utilization and control of C. megacephala.


Subject(s)
Calliphoridae/microbiology , Microbiota , Pupa/microbiology , Sequence Analysis, RNA/methods , Animals , Bacteroidetes/genetics , Bacteroidetes/isolation & purification , Bacteroidetes/physiology , Erysipelothrix/genetics , Erysipelothrix/isolation & purification , Firmicutes/genetics , Firmicutes/isolation & purification , Firmicutes/physiology , Forensic Entomology , Gammaproteobacteria/genetics , Gammaproteobacteria/isolation & purification , Gammaproteobacteria/physiology , Microbiota/genetics , Microbiota/physiology , Proteobacteria/genetics , Proteobacteria/isolation & purification , Proteobacteria/physiology , RNA, Bacterial/genetics , RNA, Ribosomal, 16S/genetics , Symbiosis , Wolbachia/genetics , Wolbachia/isolation & purification , Wolbachia/physiology
2.
Gut Microbes ; 14(1): 2013761, 2022.
Article in English | MEDLINE | ID: mdl-34965174

ABSTRACT

Fecal microbiota transplantation (FMT) is an efficient treatment for recurrent Clostridioides difficile infection and currently investigated as a treatment for other intestinal and systemic diseases. Better understanding of the species potentially transferred in FMT is needed. We isolated from a healthy fecal donor a novel strain E10-96H of Pseudoruminococcus massiliensis, a recently described strictly anaerobic species currently represented only by the type strain. The whole genome sequence of E10-96H had over 98% similarity with the type strain. E10-96H carries 20 glycoside hydrolase encoding genes, degrades starch in vitro and thus may contribute to fiber degradation, cross-feeding of other species and butyrate production in the intestinal ecosystem. The strain carries pilus-like structures, harbors pilin genes in its genome and adheres to enterocytes in vitro but does not provoke a proinflammatory response. P. massiliensis seems to have commensal behavior with the host epithelium, and its role in intestinal ecology should be studied further.


Subject(s)
Firmicutes/isolation & purification , Firmicutes/physiology , Intestines/microbiology , Adaptation, Physiological , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Butyrates/metabolism , Firmicutes/classification , Firmicutes/genetics , Gastrointestinal Microbiome , Genome, Bacterial , Glycoside Hydrolases/genetics , Glycoside Hydrolases/metabolism , Host Microbial Interactions , Humans
3.
Sci Rep ; 11(1): 23801, 2021 12 10.
Article in English | MEDLINE | ID: mdl-34893656

ABSTRACT

In this study, we used 10 healthy sheep, which gave birth to healthy twins. Stool samples were collected from mothers and their offspring 3 times during the study (0, 28 and 56 day postpartum). Milk samples were taken from the mothers at the same time. RT PCR analysis of faeces and milk was performed in order to assess the level of bacteria from the Firmicutes and Bacteroidetes phyla including the family Lactobacillaceae (phylum Firmicutes). The composition of mother's milk was also analyzed and their BCS. The data were compiled statistically. The obtained results showed that the level of the studied groups of bacteria may change due to the change of diet. Additionally, there were significant differences between lambs and mothers in the levels of the studied groups of bacteria. Analysis also shown that in the digestive system of mothers was a smaller disproportion in the level of the studied bacterial phyla than in lambs. The results also indicated the occurrence of differences in the bacterial composition at the individual level, both in ewes and their offspring. Additionally, in the conducted experiment, there were differences in the level of Firmicutes and Bacteroidetes groups depending on the sex.


Subject(s)
Firmicutes/physiology , Gastrointestinal Microbiome , Host Microbial Interactions , Lactobacillaceae/physiology , Age Factors , Animals , Biodiversity , Body Weight , Feces/microbiology , Metagenome , Metagenomics/methods , Milk , Sheep
4.
Bioengineered ; 12(2): 11947-11958, 2021 12.
Article in English | MEDLINE | ID: mdl-34818970

ABSTRACT

Type 2 diabetes mellitus (T2DM) is known as a complex genetic disease characterized by genetic and environmental factors. The imbalanced intestinal flora and intestinal mucosal barrier are considered to be related to T2DM. Curcumin has been proved to affect the progression of T2DM. T2DM animal was established by low-dose streptozotocin intraperitoneal injection combined with high-fat diet (HFD) feeding. Hematoxylin and eosin (HE) staining and transfer electron microscopy (TEM) were used to observe morphological changes of intestinal tissues of T2DM rats. Insulin and glucose tolerance tests were performed to investigate the influence of curcumin on blood glucose. Curcumin significantly improved the intestinal integrity, hyperglycemia and insulin resistance in diabetic rats. The metabolic endotoxemia induced by HFD in diabetic rats was inhibited remarkably. Curcumin reversed gut microbiota dysbiosis in diabetic rats caused by HFD. We demonstrated that curcumin could protect intestinal mucosal barrier, improve insulin resistance and reduce blood glucose in diabetic rats. This study might provide experimental evidence for the prevention and treatment in T2DM.


Subject(s)
Curcumin/pharmacology , Diabetes Mellitus, Type 2/complications , Endotoxemia/metabolism , Gastrointestinal Microbiome , Intestines/pathology , Intestines/physiopathology , Animals , Bacteroidetes/physiology , Bifidobacterium/physiology , Diet, High-Fat , Endotoxemia/complications , Firmicutes/physiology , Gastrointestinal Microbiome/drug effects , Gene Ontology , Hyperglycemia/complications , Insulin Resistance , Intestines/drug effects , Lipopolysaccharides , Metabolomics , Mice , NF-kappa B/metabolism , Rats , Signal Transduction/drug effects , Tight Junction Proteins/metabolism , Toll-Like Receptor 4/metabolism , Tumor Necrosis Factor-alpha/metabolism
5.
Anaerobe ; 72: 102459, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34555513

ABSTRACT

Infective endocarditis caused by Parvimonas micra is rare. Its clinical features are presented in this systematic review. We also describe the case of an 82-year-old man with infective endocarditis and pacemaker infection due to P. micra. There are some reports of recurrence during antimicrobial therapy; hence, careful follow-up is necessary.


Subject(s)
Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/microbiology , Firmicutes/physiology , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/microbiology , Pacemaker, Artificial/microbiology , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Biomarkers , Disease Management , Disease Susceptibility , Echocardiography , Endocarditis, Bacterial/drug therapy , Gram-Positive Bacterial Infections/drug therapy , Humans , Male , Symptom Assessment , Tomography, X-Ray Computed/methods , Treatment Outcome
6.
Nutrients ; 13(8)2021 Jul 23.
Article in English | MEDLINE | ID: mdl-34444674

ABSTRACT

Changes in the composition and proportions of the gut microbiota may be associated with numerous diseases, including cognitive impairment. Over the recent years, the growing interest in this relation is observed, but there are still many unknowns, especially in the elderly. To the best of our knowledge, this is the first work that synthesizes and critically evaluates existing evidence on the possible association between human gut microbiota and cognitive function in the elderly. For this purpose, comprehensive literature searches were conducted using the electronic databases PubMed, Google Scholar, and ScienceDirect. The gut microbiota of cognitively healthy and impaired elderly people may differ in the diversity and abundance of individual taxes, but specific taxes cannot be identified. However, some tendencies to changing the Firmicutes/Bacteroidetes ratio can be identified. Currently, clinical trials involving probiotics, prebiotics, and synbiotics supplementation have shown that there are premises for the claim that these factors can improve cognitive functions, however there is no single intervention beneficial to the elderly population. More reliable evidence from large-scale, long-period RCT is needed. Despite proposing several potential mechanisms of the gut microbiota's influence on the cognitive function impairment, prospective research on this topic is extremely difficult to conduct due to numerous confounding factors that may affect the gut microbiota. Heterogeneity of research outcomes impairs insight into these relations.


Subject(s)
Aging/physiology , Cognition/physiology , Gastrointestinal Microbiome/physiology , Probiotics/administration & dosage , Aged , Aged, 80 and over , Bacteroidetes/physiology , Cognitive Dysfunction/microbiology , Diet , Firmicutes/physiology , Humans , Prebiotics/administration & dosage
7.
Anaerobe ; 71: 102414, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34280518

ABSTRACT

Parvimonas micra (P.micra) is a difficult to culture gram positive anaerobic microorganism, typically found in the human microbiota, specially in the oral cavity. There are limited cases in literature reporting prosthetic joint infection due to this bacteria, although its isolation has been reported in different settings in later years. We present the case of a late onset knee prosthetic joint infection caused by Parvimonas micra in an 87 year old woman treated with antibiotics and two-step surgery with prosthetic material removal, antibiotic-loaded cement spacer placement and new prosthetic material replacement after 2 weeks of intravenous antimicrobial therapy followed by 6 weeks of oral therapy.


Subject(s)
Firmicutes/isolation & purification , Prosthesis-Related Infections/microbiology , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Female , Firmicutes/drug effects , Firmicutes/genetics , Firmicutes/physiology , Humans , Knee Joint/microbiology , Knee Joint/surgery , Prostheses and Implants/adverse effects , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/etiology
8.
Anaerobe ; 71: 102416, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34293443

ABSTRACT

We report a case of an immunocompetent man who presented with Desulfovibrio fairfieldensis bacteremia, followed by an epidural abscess due to Parvimonas micra. Only few cases have described unique clinical features related to both organisms, and this report illustrates two distinct sequential, if not concurrent, syndromes due to these anaerobes.


Subject(s)
Bacteremia/microbiology , Desulfovibrio/isolation & purification , Firmicutes/isolation & purification , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/immunology , Desulfovibrio/drug effects , Desulfovibrio/genetics , Desulfovibrio/physiology , Epidural Abscess/drug therapy , Epidural Abscess/microbiology , Female , Firmicutes/drug effects , Firmicutes/genetics , Firmicutes/physiology , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Humans , Immunocompromised Host , Male , Middle Aged , Young Adult
9.
Anaerobe ; 71: 102412, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34217826

ABSTRACT

Parvimonas micra is an anaerobic, fastidious, gram positive organism commonly found in the oral cavity and gastrointestinal tract. It has been increasingly reported as the cause of septic arthritis of native joints, often times with delayed diagnosis leading to increased morbidity. Risk factors include immunosuppression, inflammation of the joint, and recent dental procedures or infections. It has been a historically difficult organism to culture. However, the development of and increasing use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) has led to increased identification of P. micra. Common antibiotic susceptibilities, as well as data regarding susceptibilities in specific situations, have been reported, but susceptibility testing is required in all cases. Common treatments include clindamycin, penicillin, and metronidazole for six to ten weeks.


Subject(s)
Arthritis, Infectious/microbiology , Firmicutes/physiology , Gram-Positive Bacterial Infections/microbiology , Animals , Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/drug therapy , Firmicutes/drug effects , Firmicutes/genetics , Firmicutes/isolation & purification , Gram-Positive Bacterial Infections/drug therapy , Humans , Knee Joint/microbiology
10.
Anaerobe ; 71: 102418, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34332070

ABSTRACT

Clostridium innocuum is an anaerobic, gram-positive, spore-forming bacterium identified by Smith and King in 1962 after being isolated from a patient with an appendiceal abscess. Its name, C. innocuum, reflected its clinically "innocuous" nature based on observed lack of virulence in animal models of infection. Since that time, C. innocuum has been identified as both part of the normal intestinal flora and the cause of a rare, intrinsically vancomycin-resistant opportunistic infection in immunocompromised patients. More recently, reports from Taiwan suggest that C. innocuum, in addition to being a known extraintestinal pathogen, may also be a diarrheal pathogen that causes a C. difficile infection-like antibiotic-associated diarrheal illness. However, unanswered questions about the clinical relevance of C. innocuum remain. Here we review the microbiological and clinical characteristics of this emerging pathogen.


Subject(s)
Clostridium Infections/microbiology , Communicable Diseases, Emerging/microbiology , Firmicutes/physiology , Animals , Diarrhea/microbiology , Firmicutes/classification , Firmicutes/genetics , Firmicutes/isolation & purification , Humans
11.
BMC Microbiol ; 21(1): 165, 2021 06 03.
Article in English | MEDLINE | ID: mdl-34082713

ABSTRACT

BACKGROUND: Lactobacillus rhamnosus GG (LGG) is the most widely used probiotic, but the mechanisms underlying its beneficial effects remain unresolved. Previous studies typically inoculated LGG in hosts with established gut microbiota, limiting the understanding of specific impacts of LGG on host due to numerous interactions among LGG, commensal microbes, and the host. There has been a scarcity of studies that used gnotobiotic animals to elucidate LGG-host interaction, in particular for gaining specific insights about how it modifies the metabolome. To evaluate whether LGG affects the metabolite output of pathobionts, we inoculated with LGG gnotobiotic mice containing Propionibacterium acnes, Turicibacter sanguinis, and Staphylococcus aureus (PTS). RESULTS: 16S rRNA sequencing of fecal samples by Ion Torrent and MinION platforms showed colonization of germ-free mice by PTS or by PTS plus LGG (LTS). Although the body weights and feeding rates of mice remained similar between PTS and LTS groups, co-associating LGG with PTS led to a pronounced reduction in abundance of P. acnes in the gut. Addition of LGG or its secretome inhibited P. acnes growth in culture. After optimizing procedures for fecal metabolite extraction and metabolomic liquid chromatography-mass spectrometry analysis, unsupervised and supervised multivariate analyses revealed a distinct separation among fecal metabolites of PTS, LTS, and germ-free groups. Variables-important-in-projection scores showed that LGG colonization robustly diminished guanine, ornitihine, and sorbitol while significantly elevating acetylated amino acids, ribitol, indolelactic acid, and histamine. In addition, carnitine, betaine, and glutamate increased while thymidine, quinic acid and biotin were reduced in both PTS and LTS groups. Furthermore, LGG association reduced intestinal mucosal expression levels of inflammatory cytokines, such as IL-1α, IL-1ß and TNF-α. CONCLUSIONS: LGG co-association had a negative impact on colonization of P. acnes, and markedly altered the metabolic output and inflammatory response elicited by pathobionts.


Subject(s)
Gram-Positive Bacterial Infections/microbiology , Lacticaseibacillus rhamnosus/metabolism , Probiotics/administration & dosage , Animals , Cytokines/genetics , Cytokines/metabolism , Female , Firmicutes/growth & development , Firmicutes/physiology , Gastrointestinal Microbiome/drug effects , Germ-Free Life , Gram-Positive Bacterial Infections/genetics , Gram-Positive Bacterial Infections/metabolism , Humans , Lacticaseibacillus rhamnosus/genetics , Male , Mice , Mice, Inbred C57BL , Propionibacterium acnes/growth & development , Propionibacterium acnes/physiology , Staphylococcus aureus/growth & development , Staphylococcus aureus/physiology
12.
Invest Ophthalmol Vis Sci ; 62(7): 19, 2021 06 01.
Article in English | MEDLINE | ID: mdl-34132747

ABSTRACT

Purpose: To study the association between gut microbial abundance and sight-threatening diabetic retinopathy among patients with a history of type 2 diabetes mellitus. Methods: An observational case-control study was performed using a sample population of diabetics referred to a tertiary eye institute. Sample subjects were identified as cases if they were diagnosed with sight-threatening diabetic retinopathy and controls if they were not but had at least a 10-year history of diabetes. Fecal swabs for all patients were collected for enumeration and identification of sequenced gut microbes. Statistical analyses were performed to associate the clinically relevant Bacteroidetes to Firmicutes relative abundance ratio (B/F ratio) with sight-threatening diabetic retinopathy and an optimal cutoff value for the ratio was identified using Youden's J statistics. Results: A sample size of 58 diabetic patients was selected (37 cases, 21 controls). No statistically significant difference in the relative abundance among the predominant phyla between the groups were found. In our univariate analysis, the B/F ratio was elevated in cases compared to controls (cases, 1.45; controls, 0.94; P = 0.049). However, this statistically significant difference was not seen in our multivariate regression model. Optimal cutoff value of 1.05 for the B/F ratio was identified, and significant clustering of cases above this value was noted in beta diversity plotting. Conclusions: No difference in gut microbial abundance for any particular phylum was noted between the control and diseased population. Increased gut microbial B/F ratio can be a potential biomarker for the development of sight-threatening diabetic retinopathy among type 2 diabetic patients.


Subject(s)
Bacteroidetes , Diabetes Mellitus, Type 2 , Diabetic Retinopathy , Firmicutes , Gastrointestinal Microbiome/physiology , Bacteroidetes/isolation & purification , Bacteroidetes/physiology , Biomarkers/analysis , Case-Control Studies , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/physiopathology , Diabetic Retinopathy/diagnosis , Diabetic Retinopathy/epidemiology , Diabetic Retinopathy/etiology , Feces/microbiology , Female , Firmicutes/isolation & purification , Firmicutes/physiology , Humans , India/epidemiology , Male , Middle Aged , Risk Assessment/methods , Risk Factors , Severity of Illness Index
13.
FASEB J ; 35(7): e21734, 2021 07.
Article in English | MEDLINE | ID: mdl-34143451

ABSTRACT

Impaired glucose homeostasis in obesity is mitigated by enhancing the glucoregulatory actions of glucagon-like peptide 1 (GLP-1), and thus, strategies that improve GLP-1 sensitivity and secretion have therapeutic potential for the treatment of type 2 diabetes. This study shows that Holdemanella biformis, isolated from the feces of a metabolically healthy volunteer, ameliorates hyperglycemia, improves oral glucose tolerance and restores gluconeogenesis and insulin signaling in the liver of obese mice. These effects were associated with the ability of H. biformis to restore GLP-1 levels, enhancing GLP-1 neural signaling in the proximal and distal small intestine and GLP-1 sensitivity of vagal sensory neurons, and to modify the cecal abundance of unsaturated fatty acids and the bacterial species associated with metabolic health. Our findings overall suggest the potential use of H biformis in the management of type 2 diabetes in obesity to optimize the sensitivity and function of the GLP-1 system, through direct and indirect mechanisms.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/microbiology , Firmicutes/physiology , Glucagon-Like Peptide 1/metabolism , Mice, Obese/metabolism , Mice, Obese/microbiology , Animals , Blood Glucose/metabolism , Disease Models, Animal , Gluconeogenesis/physiology , Glucose/metabolism , Glucose Tolerance Test/methods , Hyperglycemia/metabolism , Insulin/metabolism , Mice , Mice, Inbred C57BL , Obesity/metabolism , Obesity/microbiology
14.
Nat Commun ; 12(1): 2907, 2021 05 18.
Article in English | MEDLINE | ID: mdl-34006865

ABSTRACT

We propose microbiome disease "architectures": linking >1 million microbial features (species, pathways, and genes) to 7 host phenotypes from 13 cohorts using a pipeline designed to identify associations that are robust to analytical model choice. Here, we quantify conservation and heterogeneity in microbiome-disease associations, using gene-level analysis to identify strain-specific, cross-disease, positive and negative associations. We find coronary artery disease, inflammatory bowel diseases, and liver cirrhosis to share gene-level signatures ascribed to the Streptococcus genus. Type 2 diabetes, by comparison, has a distinct metagenomic signature not linked to any one specific species or genus. We additionally find that at the species-level, the prior-reported connection between Solobacterium moorei and colorectal cancer is not consistently identified across models-however, our gene-level analysis unveils a group of robust, strain-specific gene associations. Finally, we validate our findings regarding colorectal cancer and inflammatory bowel diseases in independent cohorts and identify that features inversely associated with disease tend to be less reproducible than features enriched in disease. Overall, our work is not only a step towards gene-based, cross-disease microbiome diagnostic indicators, but it also illuminates the nuances of the genetic architecture of the human microbiome, including tension between gene- and species-level associations.


Subject(s)
Computational Biology/methods , Gastrointestinal Microbiome/genetics , Metagenome/genetics , Metagenomics/methods , Microbiota/genetics , Bacteria/classification , Bacteria/genetics , Cluster Analysis , Colorectal Neoplasms/genetics , Colorectal Neoplasms/microbiology , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/microbiology , Firmicutes/genetics , Firmicutes/physiology , Humans , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/microbiology , Microbiota/physiology , Phylogeny , Species Specificity
15.
Genome Med ; 13(1): 35, 2021 02 28.
Article in English | MEDLINE | ID: mdl-33648559

ABSTRACT

BACKGROUND: Immunoglobulin G4-related disease (IgG4-RD) and systemic sclerosis (SSc) are rare autoimmune diseases characterized by the presence of CD4+ cytotoxic T cells in the blood as well as inflammation and fibrosis in various organs, but they have no established etiologies. Similar to other autoimmune diseases, the gut microbiome might encode disease-triggering or disease-sustaining factors. METHODS: The gut microbiomes from IgG4-RD and SSc patients as well as healthy individuals with no recent antibiotic treatment were studied by metagenomic sequencing of stool DNA. De novo assembly-based taxonomic and functional characterization, followed by association and accessory gene set enrichment analysis, were applied to describe microbiome changes associated with both diseases. RESULTS: Microbiomes of IgG4-RD and SSc patients distinctly separated from those of healthy controls: numerous opportunistic pathogenic Clostridium and typically oral Streptococcus species were significantly overabundant, while Alistipes, Bacteroides, and butyrate-producing species were depleted in the two diseases compared to healthy controls. Accessory gene content analysis in these species revealed an enrichment of Th17-activating Eggerthella lenta strains in IgG4-RD and SSc and a preferential colonization of a homocysteine-producing strain of Clostridium bolteae in SSc. Overabundance of the classical mevalonate pathway, hydroxyproline dehydratase, and fibronectin-binding protein in disease microbiomes reflects potential functional differences in host immune recognition and extracellular matrix utilization associated with fibrosis. Strikingly, the majority of species that were differentially abundant in IgG4-RD and SSc compared to controls showed the same directionality in both diseases. Compared with multiple sclerosis and rheumatoid arthritis, the gut microbiomes of IgG4-RD and SSc showed similar signatures; in contrast, the most differentially abundant taxa were not the facultative anaerobes consistently identified in inflammatory bowel diseases, suggesting the microbial signatures of IgG4-RD and SSc do not result from mucosal inflammation and decreased anaerobism. CONCLUSIONS: These results provide an initial characterization of gut microbiome ecology in fibrosis-prone IgG4-RD and SSc and reveal microbial functions that offer insights into the pathophysiology of these rare diseases.


Subject(s)
Gastrointestinal Microbiome , Immunoglobulin G4-Related Disease/microbiology , Scleroderma, Systemic/microbiology , Bacteroidetes/physiology , Case-Control Studies , Cohort Studies , Extracellular Matrix/metabolism , Fibrosis , Firmicutes/physiology , Humans , Signal Transduction , Species Specificity
16.
BMC Med Genet ; 21(1): 204, 2020 10 15.
Article in English | MEDLINE | ID: mdl-33059653

ABSTRACT

BACKGROUND: Genetic analyses have identified many variants associated with the risk of inflammatory bowel disease (IBD) development. Among these variants, the ones located within the NOD2 gene have the highest odds ratio of all IBD genetic risk variants. Also, patients with Crohn's disease (CD) have been shown to have an altered gut microbiome, which might be a reflection of inflammation itself or an effect of other parameters that contribute to the risk of the disease. Since NOD2 is an intracellular pattern recognition receptor that senses bacterial peptidoglycan in the cytosol and stimulates the host immune response (Al Nabhani et al., PLoS Pathog 13:e1006177, 2017), it is hypothesized that NOD2 variants represent perfect candidates for influencing host-microbiome interactions. We hypothesized that NOD2 risk variants affect the microbiome composition of healthy first degree relative (FDR) of CD patients and thus potentially contribute to an altered microbiome state before disease onset. METHODS: Based on this, we studied a large cohort of 1546 healthy FDR of CD patients and performed a focused analysis of the association of three major CD SNPs in the coding region of the NOD2 gene, which are known to confer a 15-40-fold increased risk of developing CD in homozygous or compound heterozygous individuals. RESULTS: Our results show that carriers of the C allele at rs2066845 was significantly associated with an increase in relative abundance in the fecal bacterial family Erysipelotrichaceae. CONCLUSIONS: This result suggests that NOD2 polymorphisms contribute to fecal microbiome composition in asymptomatic individuals. Whether this modulation of the microbiome influences the future development of CD remains to be assessed.


Subject(s)
Crohn Disease/genetics , Feces/microbiology , Firmicutes/physiology , Genetic Predisposition to Disease/genetics , Nod2 Signaling Adaptor Protein/genetics , Polymorphism, Single Nucleotide , Adolescent , Adult , Alleles , Child , Cohort Studies , Crohn Disease/diagnosis , Crohn Disease/microbiology , Family , Female , Firmicutes/classification , Firmicutes/genetics , Gene Frequency , Genotype , Humans , Male , Microbiota/genetics , Microbiota/physiology , Young Adult
17.
Sci Rep ; 10(1): 13786, 2020 08 14.
Article in English | MEDLINE | ID: mdl-32796856

ABSTRACT

Biodegradable materials, including the widely used poly (lactic-co-glycolic acid) (PLGA) nanoparticles contained in slow-release drug formulations, scaffolds and implants, are ubiquitous in modern biomedicine and are considered inert or capable of being metabolized through intermediates such as lactate. However, in the presence of metabolic stress, such as in obesity, the resulting degradation products may play a detrimental role, which is still not well understood. We evaluated the effect of intravenously-administered PLGA nanoparticles on the gut-liver axis under conditions of caloric excess in C57BL/6 mice. Our results show that PLGA nanoparticles accumulate and cause gut acidification in the cecum, accompanied by significant changes in the microbiome, with a marked decrease of Firmicutes and Bacteroidetes. This was associated with transcriptomic reprogramming in the liver, with a downregulation of mitochondrial function, and an increase in key enzymatic, inflammation and cell activation pathways. No changes were observed in systemic inflammation. Metagenome analysis coupled with publicly available microarray data suggested a mechanism of impaired PLGA degradation and intestinal acidification confirming an important enterohepatic axis of metabolite-microbiome interaction resulting in maintenance of metabolic homeostasis. Thus, our results have important implications for the investigation of PLGA use in metabolically-compromised clinical and experimental settings.


Subject(s)
Gastrointestinal Microbiome/drug effects , Liver/drug effects , Obesity/genetics , Polylactic Acid-Polyglycolic Acid Copolymer/administration & dosage , Transcriptome/drug effects , Administration, Intravenous , Animals , Bacteroidetes/genetics , Bacteroidetes/physiology , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Cecum/chemistry , Cecum/drug effects , Cecum/microbiology , Disease Models, Animal , Firmicutes/genetics , Firmicutes/physiology , Gastrointestinal Microbiome/genetics , Gastrointestinal Microbiome/physiology , Humans , Hydrogen-Ion Concentration , Liver/metabolism , Mice, Inbred C57BL , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Obesity/metabolism , Polylactic Acid-Polyglycolic Acid Copolymer/chemistry
18.
Nutrients ; 12(7)2020 Jul 09.
Article in English | MEDLINE | ID: mdl-32660025

ABSTRACT

Early treatment may prevent or delay the onset of type 2 diabetes mellitus (T2DM) in individuals who are at high risk. Lifestyle interventions and the hypoglycemic drug metformin have been shown to reduce T2DM incidence. The effectiveness of such interventions may be enhanced by targeting environmental factors such as the intestinal microbiota, which has been proven to predict the response to lifestyle interventions and play a part in mediating the glucose-lowering effects of metformin. Shifts in the intestinal microbiota "towards a more balanced state" may promote glucose homeostasis by regulating short-chain fatty acids' production. This study aimed to investigate the safety and effect of a multi-strain probiotic on glycemic, inflammatory, and permeability markers in adults with prediabetes and early T2DM and to assess whether the probiotic can enhance metformin's effect on glycaemia. A randomised controlled pilot study was conducted in 60 adults with a BMI ≥ 25 kg/m2 and with prediabetes or T2DM (within the previous 12 months). The participants were randomised to a multi-strain probiotic (L. plantarum, L. bulgaricus, L. gasseri, B. breve, B. animalis sbsp. lactis, B. bifidum, S. thermophilus, and S. boulardii) or placebo for 12 weeks. Analyses of the primary outcome (fasting plasma glucose) and secondary outcomes, including, but not limited to, circulating lipopolysaccharide, zonulin, and short chain fatty acids and a metagenomic analysis of the fecal microbiome were performed at baseline and 12 weeks post-intervention. The results showed no significant differences in the primary and secondary outcome measures between the probiotic and placebo group. An analysis of a subgroup of participants taking metformin showed a decrease in fasting plasma glucose, HbA1c, insulin resistance, and zonulin; an increase in plasma butyrate concentrations; and an enrichment of microbial butyrate-producing pathways in the probiotic group but not in the placebo group. Probiotics may act as an adjunctive to metformin by increasing the production of butyrate, which may consequently enhance glucose management.


Subject(s)
Blood Glucose/analysis , Diabetes Mellitus, Type 2/blood , Gastrointestinal Microbiome , Hypoglycemic Agents/administration & dosage , Metformin/administration & dosage , Probiotics/administration & dosage , Aged , Bacteroidetes/physiology , Butyrates/blood , Fatty Acids, Volatile/blood , Female , Firmicutes/physiology , Gastrointestinal Microbiome/drug effects , Haptoglobins , Humans , Insulin Resistance , Male , Metabolic Networks and Pathways/drug effects , Middle Aged , Pilot Projects , Prediabetic State/blood , Probiotics/adverse effects , Probiotics/pharmacology , Protein Precursors/blood , Proteobacteria/physiology
19.
Arch Microbiol ; 202(10): 2629-2642, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32710156

ABSTRACT

Here we analyze the microbial community of healthy and diseased tomato plants to evaluate its impact on plant health. The organisms found in all samples mainly belonged to 4 phyla: Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria. The Proteobacteria were the highest relative abundant within the endophytic communities of different plant organs of diseased tomato. Among endophytic bacteria of tomato, only a few taxa could be cultured. Here we showed that only a few taxa of bacteria inhabiting tomato plants could be cultured and that all plant organs have a highly diverse endophytic bacterial, whose activity might affect plant growth and development as well as health. The roots seem to be an important barrier for microbes and leaves appear to be the organs with the higher diversity which is incidentally related to plant health. Fruits also contain a complex bacterial community that appeared to be unaffected by foliar diseases such as gray leaf spot at least under the conditions studied.


Subject(s)
Bacterial Physiological Phenomena , Microbiota/physiology , Plant Diseases/microbiology , Solanum lycopersicum/microbiology , Actinobacteria/physiology , Bacteria/classification , Bacteroidetes/physiology , Endophytes/classification , Firmicutes/physiology , Plant Development , Plant Roots/microbiology , Proteobacteria/physiology
20.
Clin Transl Gastroenterol ; 11(2): e00126, 2020 02.
Article in English | MEDLINE | ID: mdl-32463624

ABSTRACT

OBJECTIVES: To summarize the literature on the influence of exercise on the gut microbiota of healthy adults. METHODS: A systematic and comprehensive search in electronic database, including SciELO, Scopus, PubMed, and Web of Science up to July 5, 2019. Eligibility criterion was original studies conducted on healthy humans including exercise interventions or interventions involving any type of physical activity. RESULTS: The initial search retrieved 619 articles of which 18 met the inclusion criteria, 9 were observational, 4 reported very short-term exercise interventions, and 5 reported medium/long-term exercise interventions. Higher levels of physical activity or cardiorespiratory fitness were positively associated with fecal bacterial alpha diversity. Contrasting associations were detected between both the level of physical activity and cardiorespiratory fitness and fecal counts for the phyla Firmicutes, Bacteroidetes, and Proteobacteria. Higher levels of physical activity and cardiorespiratory fitness were positively associated with the fecal concentration of short-chain fatty acids. Reports on the effects of very short-term and medium/long-term exercise interventions on the composition of the gut microbiota were inconsistent. DISCUSSION: Higher levels of physical activity and cardiorespiratory fitness are associated with higher fecal bacterial alpha diversity and with the increased representation of some phyla and certain short-chain fatty acids in the feces of healthy adults. Very short-term and medium/long-term exercise interventions seem to influence the fecal counts of some phyla. However, the heterogeneity between studies hampers any strong conclusions from being drawn. Better-designed studies are needed to unravel the possible mechanisms through which exercise might influence the composition and activity of the human gut microbiota.


Subject(s)
Exercise/physiology , Gastrointestinal Microbiome/physiology , Bacteroidetes/isolation & purification , Bacteroidetes/physiology , Cardiorespiratory Fitness/physiology , Clinical Trials as Topic , Feces/microbiology , Firmicutes/isolation & purification , Firmicutes/physiology , Healthy Volunteers , Humans , Observational Studies as Topic , Proteobacteria/isolation & purification , Proteobacteria/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...